 |
First Quarter 2013 Financial Results May 1, 2013 4:30 PM ET Remind me |
Pharmacyclics has no intention of updating this information, and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see the disclaimer for this website.
Pharmacyclics Inc. (Nasdaq: PCYC) is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. Our pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases with critical unmet needs. Currently, we have three candidates in clinical development and several molecules in preclinical development.
- Ibrutinib (PCI-32765), first-in-human, oral therapy that is a selective, irreversible Bruton's tyrosine kinase (BTK) inhibitor being investigated in B-cell hematologic malignancies.
- PCI-27483, a subcutaneously administered Factor VIIa inhibitor targeting tissue factor expressing tumors in oncology (being investigated in pancreatic cancer).
- Abexinostat hydrochloride (PCI-24781), an oral Histone Deacetylase (HDAC) inhibitor being investigated in oncology applications, such as lymphomas and solid tumor malignancies.
- BTK Inhibitor compounds for autoimmune diseases in preclinical development.
- Isoform selective HDAC8 inhibitors in preclinical development.
Recent Releases
May 1, 2013
Pharmacyclics Reports First Quarter 2013 Results
Apr 24, 2013
Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
Events
 |
May 1, 2013 | First Quarter 2013 Financial Results |
|
Feb 14, 2013 | Pharmacyclics Inc. Financial Results for Three and Six Months Financial Results |
